Derazantinib; ARQ-087
Alaye ọja
ọja Tags
| Iwọn Pack | Wiwa | Iye owo (USD) |
| 10mg | O wa | 800 |
| 100mg | O wa | 1200 |
| 500mg | O wa | 1800 |
| Awọn iwọn diẹ sii | Gba Awọn asọye | Gba Awọn asọye |
Orukọ Kemikali:
(6R) -6- (2-fluorophenyl) -5,6-dihydro-N-[3-[2-[(2-methoxyethyl) amino] ethyl] phenyl] -Benzo [h] quinazolin-2-amine
KỌỌDỌ SMILES:
COCCNCCC1=CC(NC2=NC=C3C[C@@H](C4=CC=CC=C4F)C5=CC=CC=C5C3=N2)=CC=C1
Koodu InChi:
InChi=1S/C29H29FN4O/c1-35-16-15-31-14-13-20-7-6-8-22(17-20)33-29-32-19-21-18-26(24- 10-4-5-12-2 7 (24)30)23-9-2-3-11-25(23)28(21)34-29/h2-12,17,19,26,31H,13-16,18H2,1H3,(H) ,32,33,34)/t26-/m1/s1
Bọtini InChi:
KPJDVVCDVBFRMU-AREMUKBSSA-N
Koko-ọrọ:
Derazantinib, ARQ-087, ARQ087, ARQ 087, 1234356-69-4
Solubility:Tiotuka ni DMSO
Ibi ipamọ:0 - 4°C fun igba kukuru (ọjọ si awọn ọsẹ), tabi -20°C fun igba pipẹ (osu).
Apejuwe:
Derazantinib, ti a tun mọ ni ARQ-087, jẹ inhibitor ti ẹnu bioavailable ti olugba idagba ifosiwewe fibroblast (FGFR) pẹlu iṣẹ ṣiṣe antineoplastic ti o pọju. FGFR inhibitor ARQ 087 sopọ si ati ni agbara ṣe idiwọ iṣẹ ṣiṣe ti awọn subtypes FGFR 1, 2 ati 3. Eyi le ja si ni idinamọ awọn ipa ọna transduction ti FGFR-aladede, itọsi sẹẹli tumo, angiogenesis tumo ati iku sẹẹli tumo ni FGFR-overexpressing awọn sẹẹli tumo. . FGFR, olugba tyrosine kinase, ti wa ni atunṣe ni ọpọlọpọ awọn iru sẹẹli tumo ati ki o ṣe ipa pataki ninu ilọsiwaju cellular tumor, iyatọ, angiogenesis ati iwalaaye.
afojusun: FGFR
